

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/777,543	02/12/2004	Harold M. Bates	C015043/0174944	9840
7590 10/10/2006			EXAMINER	
Stephen P. Gilbert, Esq. BRYAN CAVE LLP			VENCI, DAVID J	
1290 Avenue of the Americas			ART UNIT	PAPER NUMBER
New York, NY 10104			1641	
			DATE MAILED: 10/10/2006	5

Please find below and/or attached an Office communication concerning this application or proceeding.

U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06)

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date _

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.

6) Other:

Notice of Informal Patent Application

Application/Control Number: 10/777,543

Art Unit: 1641

Election/Restrictions

Page 2

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-9, 11-13 and 15-30, 32-34 and 36-42, drawn to methods comprising

"asymptomatic patients", classified in class 434/156, for example.

II. Claims 43-88, drawn to methods comprising patients staged for coronary artery disease,

classified in class 436/815, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed

as capable of use together and they have different designs, modes of operation, and effects (MPEP §

802.01 and § 806.06). In the instant case, the different inventions have different modes of operation

because Invention I requires a contradiction, while invention II requires patients staged for coronary artery

disease.

Examination burden is established because the scope of prior art search required for Group I is indefinite

and therefore not coextensive with the scope of prior art search required for Group II.

This application contains claims directed to the following patentably distinct species:

A. Select ONE atherogenic protein from:

a. OxLDL;

b. mAb-4E6 antigen;

c. mAb-1H11 antigen; OR

Art Unit: 1641

d. mAb-8A2 antigen.

B. Select ONE acute phase reactant from:

- a. C-reactive protein;
- b. Serum amyloid A;
- c. Von Willebrand factor;
- d. Ferritin;
- e. Fibrinogen;
- f. Albumin;
- g. Apo A-I;
- h. Apo A-II; OR
- i. HDL.

C. Select ONE stage from:

- a. Stable angina;
- b. Acute coronary syndrome;
- c. Unstable angina; OR
- d. Acute myocardial infarction.

Applicant is required under 35 U.S.C. 121 to elect ONE disclosed species from each of A, B, and C for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held allowable. Currently, claims 1, 22, 43 and 66 are generic.

The species are independent or distinct because each protein requires search for a different assay. In addition, the expression of each protein does not appear similar among the different stages.

Art Unit: 1641

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that a complete reply to this requirement must include: (i) an election of a species or invention to be examined even if the requirement is traversed¹ (37 CFR 1.143), and (ii) identification of the claims encompassing the elected invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Venci whose telephone number is 571-272-2879. The examiner can normally be reached on 08:00 - 16:30 (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Applicant may elect an invention or species with traverse or without traverse. To reserve a right to petition, Applicant must elect with traverse. Should Applicant traverse on the ground that the inventions or species are not patentably distinct, Applicant should clearly admit on the record, or submit or identify evidence on the record that the inventions or species are obvious variants. If Examiner finds one Inventions unpatentable over the prior art, Examiner may use the evidence or admission of record to reject other inventions under 35 U.S.C.103(a).

Application/Control Number: 10/777,543

Art Unit: 1641

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

David J Venci Examiner Art Unit 1641

div

LONG V. LE 09/29/06 SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600